(AllianceNews) – RTW Biotech Opportunities announced Tuesday that it has made several new investments in private portfolio companies named Mirador Therapeutics and Santa Ana Bio.
RTW Biotech is an investment fund managed by RTW Investments LP that focuses on acquiring transformative assets in the life sciences sector. The company’s shares were down 0.7% to trade at $1.52 per share on Tuesday morning in London.
Mirador Therapeutics is a next-generation precision medicine company focused on immunology and inflammation, and Santa Ana Bio is a biotechnology company developing a pipeline of therapeutics that unlock the full potential of precision medicine.
Along with other investment vehicles, RTW Biotech participated in Mirador’s Series A funding round, raising more than $400 million in preparation for its March launch.
The company also participated in Santa Ana’s Series A funding round, which raised $168 million in May.
“We are active in private investing again and see a lot of opportunities. After a few years of subdued investments as we focused on public market opportunities, we expect to return to our more normal pace of around 12 private deals per year, as long as IPO activity remains strong,” said chief investment officer Rod Wong.
Holly Beveridge, Senior Reporter, Alliance News
If you have any comments or questions please contact newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All rights reserved.
